Comparison of Effectiveness of Drug-Coated Balloon Angioplasty versus Plain Balloon Angioplasty in Chronic Lower Extremity Ischemia Patients

• Main Authors: Nazari I, Mousavi SM, Sadeghpour A, Alamshah SM, Dastoorpoor M
• Format: Article
• Language: English
• Published: Dove Medical Press 2020-09-01
• Series: International Journal of General Medicine
• Subjects: angioplasty; drug coated balloon; paclitaxel; peripheral vascular disease
• Online Access: https://www.dovepress.com/comparison-of-effectiveness-of-drug-coated-balloon-angioplasty-versus--peer-reviewed-article-IJGM

Iraj Nazari,1 Seyyed Masoud Mousavi,1 Ahmad Sadeghpour,1 Seyyed Mansour Alamshah,1 Maryam Dastoorpoor2 1Department of General Surgery, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; 2Department of Biostatistics and Epidemiology, Menopause Andropause Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IranCorrespondence: Ahmad SadeghpourDepartment of General Surgery, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IranEmail [e-mail]: Occlusive lesions of superficial femoral artery (SFA) in endovascular candidate patients are treated with balloon angioplasty with or without stenting. Recently, introduction of drug-coated balloon (DCB) angioplasty as a superior treatment option to plain balloon (PB) has been challenging.Objective: The purpose of this study was to compare the effectiveness of DCB versus PB angioplasty in chronic lower extremity ischemia patients.Patients and Methods: In this clinical trial, 2 groups were matched at baseline; among 68 patients with peripheral artery disease, 23 patients were treated by DCB and 45 by PB. They were followed up for 6 months. Our findings of ABI, Rutherford and WIFI class changes, mortality, limb amputation, re-intervention and primary patency (PP) were collected and analyzed in comparative fashion between 2 groups.Results: Mean patients age was 68.5 years (77.9% male). At 6 months, the increase in ABI in DCB was 0.37 and in PB was 0.32 (P> 0.05). Mean decrease in Rutherford class in DCB and PB were 2.56, 2.28 (P> 0.05). Mean decrease in WIFI class in DCB and PB were 1.48, 1.11 (P> 0.05). In DCB group, 1 (4.3%) limb amputation, 3 (13%) re-interventions and no mortality with 87% PP were seen. In PB group, 2 (4.4%) limb amputation, 7 (15.6%) re-interventions, 1 (2.2%) mortality with 84.4% PP were seen.Conclusion: Treatment of occlusive lesions of SFA with DCB probably may leads to improvement in ABI, Rutherford and WIFI class, higher pp and lower rate of re-interventions. Since Rutherford class and pp in DCB group have improved during 6 months compared to 1 month follow up (in our study), this improvement seems to be more significant statistically in longer term of follow up.Keywords: angioplasty, drug-coated balloon; DCB, paclitaxel, peripheral vascular disease